This ADC product is comprised of an anti-EPCAM monoclonal antibody (MOC31) conjugated via a hydrazone linker to Doxorubicin. The Doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Doxorubicin binds to DNA, causes DNA damage.
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy.
ADC Antibody
Overview
Anti-EpCAM Antibody, MOC31
Generic name
MOC31
Species Reactivity
Human
ADC Linker
Name
acid-cleavable hydrazone linker
Description
Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
ADC payload drug
Name
doxorubicin
Description
Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.